Study S001516

Effect of Semaglutide on Coronary Atherosclerosis Plaque Progression in Type 2 Diabetics

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03985384
Acronym: STOP
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 140
Start: 2019-04-30
Primary completion: 2022-12-27
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Conditions: Type 2 Diabetes; Coronary Artery Disease
Interventions: DRUG:Semaglutide 2 MG/1.5 ML Subcutaneous Solution; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Rate of change in non-calcified plaque volume [12 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.